AngioDynamics Third Quarter Net Income up 73% on Record Revenue; Company Revises Financial Guidance Upwards; Conference Call Begins Today at 4:30 p.m. ET.QUEENSBURY, NY -- AngioDynamics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ANGO ANGO Algemene Nederlandse Gehandicapten Organisatie (Dutch: Equal Opportunities for Persons with Disabilities) ) today announced financial results for the 13 and 39 weeks ended February 25, 2006. Financial highlights of the third quarter of fiscal year 2006 (December through February) include: --Net sales up 28% over the fiscal 2005 third quarter to a record $19.8 million --Net income up 73% over the fiscal 2005 third quarter to $1.9 million, or $0.14 per diluted share --Gross profit up 35% over the fiscal 2005 third quarter to $11.5 million --Gross profit margin up 300 basis points over the fiscal 2005 third quarter to 58% Net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight for the third quarter of fiscal 2006 increased 28% to $19.8 million, up from $15.5 million for the third quarter of fiscal 2005. This increase was primarily due to strong growth from the Company's newest products, along with continued market share gains across our diversified product portfolio. All of the revenue gains were due to increases in unit sales unit sales Sales measured in terms of physical units rather than dollars. Unit sales data are often used by financial analysts when evaluating the health of a company. . Sales of angiographic products were $5.3 million, an increase of 16%, or $730,000, over the third quarter of fiscal 2005. Sales of dialysis dialysis (dīăl`ĭsĭs), in chemistry, transfer of solute (dissolved solids) across a semipermeable membrane. Strictly speaking, dialysis refers only to the transfer of the solute; transfer of the solvent is called osmosis. products were $5.0 million, an increase of 19%, or $801,000, over the prior year third quarter. Sales of Dura-Flow(TM) chronic dialysis catheters A dialysis catheter is a catheter used for exchanging blood to and from the hemodialysis machine from the patient. The dialysis catheter contains two lumens:
Net income for the fiscal 2006 third quarter was $1.9 million, or $0.14 per diluted share. This represents a 73% increase in net income and a 56% increase in diluted earnings per share diluted earnings per share An earnings measure calculated by dividing net income less preferred stock dividends for a period by the average number of shares of common stock that would be outstanding if all convertible securities were converted into shares of over the prior year third quarter. Gross profit for the third quarter of fiscal 2006 increased 35%, to $11.5 million, compared with $8.6 million for the prior year third quarter. Gross profit margin Gross profit margin Gross profit divided by sales, which is equal to each sales dollar left over after paying for the cost of goods sold. gross profit margin A measure calculated by dividing gross profit by net sales. for the fiscal 2006 quarter increased 300 basis points to 58%, up from 55% for the comparable fiscal 2005 quarter. The increase in gross profit margin was largely the result of a favorable product mix from increased sales of higher margin products, such as our Morpheus CT PICC, EVENMORE dialysis catheters and VenaCure disposable kits, as well as production efficiencies resulting from continuous efforts to streamline the manufacturing process. Operating profit Operating profit (or loss) Revenue from a firm's regular activities less costs and expenses and before income deductions. operating profit See operating income. for the fiscal third quarter increased 35% to $2.9 million, or 15% of net sales, compared with $2.1 million, or 14% of net sales, for the third quarter of fiscal year 2005. "We are extremely proud to continue to post record sales, spurred by excellent unit growth across our key product lines," commented Eamonn P. Hobbs, president and chief executive officer of AngioDynamics. "We began our nationwide launch of the TOTAL ABSCESSION(TM) general drainage catheter in December, and with sales of $221,000 for the fiscal quarter, we are off to a healthy start." "We continue to be pleased with the strong uptake of our VenaCure product line for the treatment of severe varicose veins Varicose Veins Definition Varicose veins are dilated, tortuous, elongated superficial veins that are usually seen in the legs. Description . The 81% increase in sales this quarter over the prior year third quarter is especially gratifying grat·i·fy tr.v. grat·i·fied, grat·i·fy·ing, grat·i·fies 1. To please or satisfy: His achievement gratified his father. See Synonyms at please. 2. ," added Mr. Hobbs. "We sold 29 lasers in the fiscal third quarter and sales of our VenaCure disposable kits, which provide a significant source of high-margin recurring re·cur intr.v. re·curred, re·cur·ring, re·curs 1. To happen, come up, or show up again or repeatedly. 2. To return to one's attention or memory. 3. To return in thought or discourse. revenues, more than doubled over the third quarter of fiscal 2005." "We also began selling Sotradecol(TM) in mid-January to interventional radiologists, vascular surgeons and general surgeons General surgeon A physician who has special training and expertise in performing a variety of operations. Mentioned in: Appendectomy for the treatment of small, uncomplicated varicose veins, following its showcase at the 19th Annual Congress of the American College American College is the name of:
n. The branch of medicine that deals with veins and their diseases. phle·bol  o·gist n. meeting held in November. We expect that Sotradecol will be
an important contributor to our vein treatment product line going
forward," remarked Mr. Hobbs.As of February 25, 2006, cash and short-term investments were $28.9 million, compared with $27.1 million as of May 28, 2005. During the fiscal third quarter the Company made a final installment payment of $800,000 to Bioniche Pharma Group Limited for the licensing rights to distribute Sotradecol. Operating cash flow Operating cash flow Earnings before depreciation minus taxes. Measures the cash generated from operations, not counting capital spending or working capital requirements. continues to be strong, as the Company generated $2.4 million in cash from operations during the fiscal third quarter. For the 39 weeks ended February 25, 2006, net sales were $54.9 million, up 28% from $43.0 million for the comparable 2005 period. The increase was due to expanded sales across our diversified product line, most notably our Morpheus CT PICC, Dura-Flow dialysis catheters, and our VenaCure product line. Net income for the nine months ended February 25, 2006 was $4.8 million, up 68% from $2.9 million for the comparable fiscal 2005 period, and diluted earnings per share increased to $0.37 from $0.24, up 54%. Fiscal Year 2006 Financial Guidance The Company is revising upwards its fiscal 2006 financial guidance. AngioDynamics now expects net sales growth to exceed 29% over fiscal 2005, to at least $78.0 million. Year-over-year net income growth is expected to exceed 60%, to $7.3 million, which includes an anticipated one-time charge totaling $400,000, net of income taxes, to be incurred in connection with the Company's requirement to comply by May 2006 with Section 404 of the Sarbanes-Oxley Act See SOX. . This compares with the Company's prior guidance for net sales of at least $76.0 million, and net income of at least $6.7 million for fiscal 2006. The Company now expects its earnings per diluted share to increase to $0.57 for fiscal 2006, compared with its prior guidance of $0.52 per diluted share. Without the effect of these one-time expenses, net income would be expected to reach $7.7 million, representing 69% growth over fiscal 2005. The Company is providing this guidance to aid investors in understanding the Company's projected operating results absent non-recurring expenses and to enable investors to more accurately compare future period results to the current period results without the effect of these one-time expenses. The Company expects R&D and SG&A expenses for the fiscal year 2006 to be approximately 8% and 36% of net sales, respectively. The Company is revising its effective tax rate for fiscal year 2006 to approximately 38%. Conference Call AngioDynamics management will host a conference call to discuss this announcement today beginning at 4:30 p.m. Eastern Time. To participate in the call, please dial (800) 561-2718 from the U.S., or (617) 614-3525 from outside the U.S. The passcode is 60630716. A telephone replay will be available from 6:30 p.m. Eastern Time on March 21, 2006 through 11:59 p.m. Eastern Time on March 28, 2006 by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international) and entering conference ID number 83919989. In addition, individuals can listen to the call on the Internet by visiting the investor relations Investor relations The process by which the corporation communicates with its investors. portion of the Company's web site at http://investor.angiodynamics.com/. A recording of the conference call will be archived there for 12 months. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . AngioDynamics designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic catheters, dialysis catheters, venous products, PTA PTA or parent-teacher association: see parent education. dilation dilation /di·la·tion/ (di-la´shun) 1. the act of dilating or stretching. 2. dilatation. di·la·tion n. 1. balloon catheters balloon catheter n. A catheter with an inflatable balloon at its tip, used especially to expand a partially obstructed blood vessel or bodily passage and to measure blood pressure in a blood vessel. Also called balloon-tip catheter. , image-guided vascular access products, thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. products, and drainage products. The statements made in this document contain certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. , results of pending or future clinical trials, results of pending patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations A group purchasing organization is an entity that leverages the purchasing power of a group of businesses to obtain discounts from vendors based on the collective buying power of the GPO members. Many GPOs are funded by administrative fees that are actually paid by the vendors. , competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended May 28, 2005, may affect the actual results achieved by the Company.
AngioDynamics, Inc. and Subsidiary
CONSOLIDATED INCOME STATEMENT HIGHLIGHTS
(in thousands, except shares and per share data)
Thirty-nine
Thirteen weeks ended weeks ended
--------------------------------------------
Feb 25, Feb 26, Feb 25, Feb 26,
2006 2005 2006 2005
--------------------------------------------
(unaudited) (unaudited)
Net sales $19,785 $15,450 $54,859 $42,957
Cost of goods sold 8,237 6,885 22,945 19,336
--------------------------------------------
Gross profit 11,548 8,565 31,914 23,621
--------------------------------------------
Gross profit
margin % 58.4% 55.4% 58.2% 55.0%
Operating expenses
Selling and
administrative 7,213 5,391 20,202 15,135
Research and development 1,446 1,026 4,510 3,276
--------------------------------------------
Total operating
expenses 8,659 6,417 24,712 18,411
--------------------------------------------
Operating profit 2,889 2,148 7,202 5,210
Other income (expenses),
net 224 (245) 595 (207)
--------------------------------------------
Income before income tax
provision 3,113 1,903 7,797 5,003
Income tax provision 1,233 818 2,969 2,121
--------------------------------------------
NET INCOME $1,880 $1,085 $4,828 $2,882
============================================
Earnings per common share
Basic $.15 $.09 $.39 $.25
============================================
Diluted $.14 $.09 $.37 $.24
============================================
Weighted Average Common
Shares
Basic 12,367,348 11,606,055 12,253,254 11,498,425
Diluted 12,990,650 12,481,849 12,908,800 12,192,518
AngioDynamics, Inc. and Subsidiary
CONSOLIDATED BALANCE SHEET HIGHLIGHTS
(in thousands)
Feb 25, May 28,
Assets 2006 2005
-------- --------
(2) (1)
Current Assets
Cash and Cash Equivalents $13,356 $14,498
Marketable Securities 15,551 12,601
Accounts Receivable, net 12,182 9,929
Inventories 13,137 10,264
Deferred income taxes 707 736
Other current assets 1,164 1,679
-------- --------
Total current assets 56,097 49,707
Property, Plant & Equipment - at cost, net 10,355 8,528
Other Non-Current Assets 3,775 1,437
-------- --------
Total Assets $70,227 $59,672
======== ========
Liabilities and Stockholders' Equity
Current Liabilities $10,093 $7,627
Long-term Debt 2,800 2,935
Stockholders' Equity 57,334 49,110
-------- --------
Total Liabilities and Stockholders' Equity $70,227 $59,672
======== ========
(1) Information derived from audited financial statements
(2) Unaudited
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion